Videos

ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

In-hospital mortality and complication rates were lower at accredited hospitals vs those not accredited for patients undergoing rectal cancer surgery.